Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 3Carcinoma, Transitional Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Head and Neck Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Capecitabine 22Oxaliplatin 19Fluorouracil 16Radiotherapy 11Leucovorin 10Cetuximab 9Nivolumab 7Bevacizumab 6sintilimab 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Irinotecan 5Folfox protocol 5trifluridine tipiracil drug combination 4pembrolizumab 4Surgical Procedures, Operative 4encorafenib 3X-Rays 3Trastuzumab 3Surveys and Questionnaires 3Sigmoidoscopy 3Radiation 3Pemetrexed 3Gemcitabine 3Endoscopy 3Control Groups 3Consolidation Chemotherapy 3Cisplatin 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × disitamab vedotin × 90 days × Clear all
NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡